Selecting the appropriate treatment option among the multitude of available antipsoriatic agents is one of the greatest challenges today. Empirical studies show that the therapeutic response of different biologics varies depending on patient characteristics. Patient-oriented selection criteria can counteract the problem of secondary loss of efficacy. This is especially true for first biologic therapy, as this has been shown to be an important influencing factor for “drug survival.”